Woodline Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Woodline Partners’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,941	Closed	-$90.7K	–	973
2024 Q4	$90.7K	Hold	8,941	–	–	﹤0.01%	915
2024 Q3	$111K	Hold	8,941	–	–	﹤0.01%	583
2024 Q2	$116K	Hold	8,941	–	–	﹤0.01%	541
2024 Q1	$203K	Buy	8,941 +1,160	+15%	+$20.3K	﹤0.01%	516
2023 Q4	$101K	Sell	7,781 -1,160	-13%	-$15.6K	﹤0.01%	464
2023 Q3	$180K	Buy	+8,941	New	+$201K	﹤0.01%	560
2023 Q1	–	Sell	-88,326	Closed	-$4.5M	–	709
2022 Q4	$4.5M	Sell	88,326 -12,558	-12%	-$871K	0.06%	335
2022 Q3	$8.26M	Buy	+100,884	New	+$7.54M	0.12%	220
2020 Q3	–	Sell	-30,882	Closed	-$8.77M	–	196
2020 Q2	$8.77M	Buy	+30,882	New	+$9.13M	0.35%	79
2020 Q1	–	Sell	-2,546	Closed	-$732K	–	157
2019 Q4	$732K	Buy	+2,546	New	+$552K	0.03%	105

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Woodline Partners's KPTI Position: Q1 2025 in Review

Woodline Partners sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 8,941 shares — an estimated $90.7K sold.

Woodline Partners first reported a position in KPTI in Q4 2019 and held it in 10 quarters. The position peaked at $8.77M in Q2 2020. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

Woodline Partners reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
Woodline Partners sold 8,941 Karyopharm Therapeutics shares in Q1 2025, an estimated $90.7K.
Woodline Partners first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 10 quarters.
Woodline Partners's Karyopharm Therapeutics position peaked at $8.77M in Q2 2020.
49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.